• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: vedolizumab in inflammatory bowel diseases-less is more? Authors' reply.

作者信息

Danese Silvio, Subramaniam Kavitha, Van Zyl Jan, Adsul Shashi

机构信息

IBD Center, Humanitas Clinical and Research Center - IRCCS, and Humanitas University, Department of Biomedical Sciences, Milan, Italy.

Gastroenterology and Hepatology Unit, Canberra Hospital, Canberra, ACT, Australia.

出版信息

Aliment Pharmacol Ther. 2021 Feb;53(3):445-446. doi: 10.1111/apt.16227.

DOI:10.1111/apt.16227
PMID:33428255
Abstract
摘要

相似文献

1
Editorial: vedolizumab in inflammatory bowel diseases-less is more? Authors' reply.社论：维多珠单抗治疗炎症性肠病——少即是多？作者回复。
Aliment Pharmacol Ther. 2021 Feb;53(3):445-446. doi: 10.1111/apt.16227.
2
Editorial: vedolizumab in inflammatory bowel diseases-less is more?社论：维多珠单抗治疗炎症性肠病——少即是多？
Aliment Pharmacol Ther. 2021 Feb;53(3):443-444. doi: 10.1111/apt.16191.
3
Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease-authors' reply.社论：改善炎症性肠病青少年患者维多珠单抗药代动力学的成就与未解决的问题——作者回复
Aliment Pharmacol Ther. 2023 Mar;57(5):567-568. doi: 10.1111/apt.17337.
4
Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non-elderly patients with inflammatory bowel disease-the IG-IBD LIVE study. Authors' reply.社论：维多珠单抗在炎症性肠病老年和非老年匹配队列患者中的有效性和安全性——IG-IBD LIVE研究。作者回复。
Aliment Pharmacol Ther. 2022 Aug;56(4):733-734. doi: 10.1111/apt.17076.
5
Vedolizumab (Entyvio) for inflammatory bowel disease.维多珠单抗（恩特维尤）用于治疗炎症性肠病。
Med Lett Drugs Ther. 2014 Sep 15;56(1451):86-8.
6
Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game-authors' reply.社论：抗TNF药物与维多珠单抗作为二线治疗药物的比较？平局并不意外——作者回复
Aliment Pharmacol Ther. 2021 Mar;53(5):642-643. doi: 10.1111/apt.16241.
7
Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors' reply.信函：维多珠单抗或第二种抗 TNF 药物——对炎症性肠病原发性生物制剂失效患者的疗效无差异。作者回复。
Aliment Pharmacol Ther. 2021 May;53(9):1046-1047. doi: 10.1111/apt.16352.
8
Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease.社论：改善维多珠单抗在青少年炎症性肠病患者中的药代动力学方面的成就与未解决的问题
Aliment Pharmacol Ther. 2023 Mar;57(5):565-566. doi: 10.1111/apt.17321.
9
Vedolizumab Is Safe and Effective in Elderly Patients with Inflammatory Bowel Disease.维多珠单抗在老年炎症性肠病患者中安全有效。
Inflamm Bowel Dis. 2017 Apr;23(4):E17. doi: 10.1097/MIB.0000000000001071.
10
Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease-Authors' reply.信函：维多珠单抗用于自身免疫性肝病相关的炎症性肠病——作者回复
Aliment Pharmacol Ther. 2018 May;47(10):1423-1424. doi: 10.1111/apt.14638.